3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Disease
1
Dendritic Cell Sarcoma, Interdigitating
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Temozolomide
131
Radiotherapy
87
Bevacizumab
43
Radiation
31
Carmustine
29
Magnetic Resonance Spectroscopy
22
Irinotecan
22
Erlotinib Hydrochloride
22
Chemotherapy, Adjuvant
20
Surgical Procedures, Operative
15
O(6)-benzylguanine
15
Carboplatin
14
Radiotherapy, Intensity-Modulated
13
Radiotherapy, Conformal
13
sargramostim
12
Sirolimus
9
Imatinib Mesylate
9
Filgrastim
9
Drug Therapy
9
temsirolimus
8
Thalidomide
8
Sorafenib
8
Radiosurgery
8
pembrolizumab
7
motexafin gadolinium
7
aldesleukin
7
Vorinostat
7
Procarbazine
7
Gene Expression Profiling
7
Gefitinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gliosarcoma
×
Antibodies, Monoclonal
×
Sarcoma
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled